Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Share-based Compensation (2021 - 2025)

PAVmed has reported Share-based Compensation over the past 5 years, most recently at -$970000.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at -$970000.0 for Q4 2025, down 232.33% from a year ago — trailing twelve months through Dec 2025 was $505000.0 (down 92.22% YoY), and the annual figure for FY2025 was $505000.0, down 92.17%.
  • Share-based Compensation for Q4 2025 was -$970000.0 at PAVmed, down from $383000.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for PAVM hit a ceiling of $5.2 million in Q2 2021 and a floor of -$970000.0 in Q4 2025.
  • Median Share-based Compensation over the past 5 years was $2.2 million (2023), compared with a mean of $2.7 million.
  • Biggest five-year swings in Share-based Compensation: soared 235.24% in 2022 and later plummeted 232.33% in 2025.
  • PAVmed's Share-based Compensation stood at $4.4 million in 2021, then grew by 12.99% to $4.9 million in 2022, then plummeted by 60.23% to $2.0 million in 2023, then plummeted by 62.75% to $733000.0 in 2024, then plummeted by 232.33% to -$970000.0 in 2025.
  • The last three reported values for Share-based Compensation were -$970000.0 (Q4 2025), $383000.0 (Q3 2025), and $162000.0 (Q2 2025) per Business Quant data.